Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma
  1. Home
  2. Publications
  3. Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma

Real-world patterns of first-line treatment selection after the introduction of enfortumab vedotin plus pembrolizumab for advanced urothelial carcinoma

Authors:
  • TNTakuma Narita
    Takuma Narita
  • YSYuya Sekine
    Yuya Sekine
  • MSMasanao Shinohara
    Masanao Shinohara
  • NFNaoki Fujita
    Naoki Fujita
  • YKYohei Kawashima
    Yohei Kawashima
  • SNShintaro Narita
    Shintaro Narita
  • SKShin Kobayashi
    Shin Kobayashi
  • JMJotaro Mikami
    Jotaro Mikami
  • TOTeppei Okamoto
    Teppei Okamoto
  • HYHayato Yamamoto
    Hayato Yamamoto

Open Access
Publisher website
Google Scholar
  • 25 August 2026
    • journal article
    • research article
    • Published by Springer Nature in BMC Cancer
    • DOI:10.1186/s12885-026-16841-2
Abstract
No abstract available
Keywords
  • ADVANCED UROTHELIAL CARCINOMA
  • ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB
  • FIRST-LINE TREATMENT
  • REAL-WORLD STUDY
  • TREATMENT SELECTION
  • PERFORMANCE STATUS
All Related Versions
  • Version 1, 2026-07-27, Research Square
Funding Information
  • Japan Society for the Promotion of Science (25K02769)
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.